title: Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity.
abstract: Alzheimer's disease (AD) is the most common neurodegenerative disease and the leading cause of dementia. In addition to grey matter pathology, white matter changes are now recognized as an important pathological feature in the emergence of the disease. Despite growing recognition of the importance of white matter abnormalities in the pathogenesis of AD, the causes of white matter degeneration are still unknown. While multiple studies propose Wallerian-like degeneration as the source of white matter change, others suggest that primary white matter pathology may be due, at least in part, to other mechanisms, including local effects of toxic Aβ peptides. In the current study, we investigated levels of soluble amyloid-beta (Aβ) in white matter of AD patients (n=12) compared with controls (n=10). Fresh frozen white matter samples were obtained from anterior (Brodmann area 9) and posterior (Brodmann area 1, 2 and 3) areas of post-mortem AD and control brains. ELISA was used to examine levels of soluble Aβ -42 and Aβ -40. Total cortical neuritic plaque severity rating was derived from individual ratings in the following areas of cortex: mid-frontal, superior temporal, pre-central, inferior parietal, hippocampus (CA1), subiculum, entorhinal cortex, transentorhinal cortex, inferior temporal, amygdala and basal forebrain. Compared with controls, AD samples had higher white matter levels of both soluble Aβ -42 and Aβ -40. While no regional white matter differences were found in Aβ -40, Aβ -42 levels were higher in anterior regions than in posterior regions across both groups. After statistically controlling for total cortical neuritic plaque severity, differences in both soluble Aβ -42 and Aβ -40 between the groups remained, suggesting that white matter Aβ peptides accumulate independent of overall grey matter fibrillar amyloid pathology and are not simply a reflection of overall amyloid burden. These results shed light on one potential mechanism through which white matter degeneration may occur in AD. Given that white matter degeneration may be an early marker of disease, preceding grey matter atrophy, understanding the mechanisms and risk factors that may lead to white matter loss could help to identify those at high risk and to intervene earlier in the pathogenic process.
authors.forename: Lyndsey E
authors.initials: LE
authors.lastname: Collins-Praino
authors.forename: Yitshak I
authors.initials: YI
authors.lastname: Francis
authors.forename: Erica Y
authors.initials: EY
authors.lastname: Griffith
authors.forename: Anne F
authors.initials: AF
authors.lastname: Wiegman
authors.forename: Jonathan
authors.initials: J
authors.lastname: Urbach
authors.forename: Arlene
authors.initials: A
authors.lastname: Lawton
authors.forename: Lawrence S
authors.initials: LS
authors.lastname: Honig
authors.forename: Etty
authors.initials: E
authors.lastname: Cortes
authors.forename: Jean Paul G
authors.initials: JP
authors.lastname: Vonsattel
authors.forename: Peter D
authors.initials: PD
authors.lastname: Canoll
authors.forename: James E
authors.initials: JE
authors.lastname: Goldman
authors.affiliation: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York 10032, NY, USA. amb2139@columbia.edu.
authors.forename: Adam M
authors.initials: AM
authors.lastname: Brickman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000378:metabolism*; D002540:Cerebral Cortex / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D058225:Plaque, Amyloid / Q000378:metabolism*; D066127:White Matter / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides